Free Trial
Final Hours! MarketBeat All Access at $149 Until 11:59 PM
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149 Tonight
Claim MarketBeat All Access Sale Promotion
NYSE:OGN

Organon & Co. Q3 2026 Earnings Date & Estimates

Organon & Co. logo
$13.82 +0.01 (+0.04%)
As of 12:47 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Organon & Co. is estimated to report Q3 2026 earnings on Friday, October 30, 2026, before market opens. The conference call is scheduled for 7:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
7:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Organon & Co. in Q3 2026

Organon & Co. is expected to post earnings of $0.95 per share. In the same quarter a year earlier Organon & Co. reported $1.01 per share on revenue of $1.60 billion. Organon & Co. last reported on April 30, 2026, posting $0.71 per share and missing the $0.83 consensus estimate. Organon & Co. has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.95
Prior-Year EPS
$1.01
Prior-Year Revenue
$1.60 billion
Expected EPS Growth
-5.9%

Recent Track Record

Last Reported
Q1 2026
Last Quarter EPS
$0.71 (Missed by -$0.12)
Last Quarter Revenue
$1.46 billion
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Powered by Quartr

Earnings Documents

Organon & Co.'s Q3 2026 Quarterly reportQuarterly report
(10-Q)

Organon & Co. Q3 2026 Earnings FAQ

Organon & Co. (NYSE:OGN) is estimated to report Q3 2026 earnings on Friday, October 30, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Organon & Co.'s Q3 2026 earnings conference call is scheduled for Friday, October 30, 2026 at 7:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Organon & Co. to post earnings of $0.95 per share for Q3 2026.

Organon & Co.'s next earnings date is estimated for Monday, November 9, 2026. MarketBeat tracks confirmed and estimated earnings dates for Organon & Co. on the company's earnings history page.

Organon & Co. Earnings Headlines

Organon Highlights Non-GAAP Metrics Amid Pending Merger
 |  tipranks.comhttps://www.tipranks.com/news/company-announcements/organon-highlights-non-gaap-metrics-amid-pending-merger?utm_source=marketbeat.com&utm_medium=referral
Organon Announces Quarterly Dividend
 |  businesswire.comhttps://www.businesswire.com/news/home/20261030977126/en/organon-announces-quarterly-dividend/
Don't lose access to this
Ian Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall. The free download walks through strategies for navigating the options market, but the window to claim it is closing soon.tc pixel
October 30 at 1:00 AM  |  TradeWins (Ad)
Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
October 19, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261019387279/en/Organon-to-Report-Third-Quarter-2026-Results-in-Its-Regularly-Scheduled-Form-10-Q-Filing/
Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting
October 16, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261016500412/en/organon-announces-positive-interim-phase-3-study-results-for-miudella%c2%ae-a-hormone-free-intrauterine-device-iud-through-6-years-of-use-to-be-presented-at-the-2026-society-of-family-planning-annual-meeting/
Organon & Co stock hits 52-week high at 13.79 USD
October 7, 2026  |  investing.comhttps://www.investing.com/news/company-news/organon--co-stock-hits-52week-high-at-1379-usd-93CH-4937393
See More Organon & Co. Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Organon & Co.? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Organon & Co. and other key companies, straight to your email.

About Organon & Co.

Organon & Co. (NYSE:OGN) is a global health care company focused on improving the health and quality of life of women throughout their lives. The company develops, manufactures and commercializes prescription medicines and other health care products, with operations serving patients and health care providers in markets around the world.

Organon’s women’s health portfolio includes contraceptive products such as Nexplanon and NuvaRing, as well as medicines and technologies related to fertility, pregnancy and other reproductive health needs. The company also markets biosimilar medicines, including treatments used in immunology and oncology, and a portfolio of established brands in areas such as cardiovascular health, respiratory disease, dermatology and pain management.

Organon became an independent, publicly traded company in June 2021 through a spin-off from Merck & Co. The company is headquartered in Jersey City, New Jersey, and its products are available in more than 140 countries. Organon is led by Chief Executive Officer Kevin Ali, who has held the role since the company’s separation from Merck.

View Organon & Co. Profile
Earnings Tools